A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal response. Safety and feasibility of therapy with ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg/kg/day) was previously established in our phase I trial (n = 12). We now report...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazaryan, Aleksandr, Lee, Stephanie, Arora, Mukta, Kim, Jongphil, Betts, Brian Christopher, Khimani, Farhad, Nishihori, Taiga, Bejanyan, Nelli, Liu, Hien, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Gonzalez, Rebecca, Jain, Michael D., Davila, Marco L., Perez, Lia Elena, Mishra, Asmita, Perez Perez, Ariel, Balke, Karlie, Ayala, Ernesto, Ochoa, Leonel, Castaneda Puglianini, Omar, Faramand, Rawan, Alsina, Melissa, Elmariah, Hany, Nieder, Michael L., Fernandez, Hugo, Anasetti, Claudio, Pidala, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753213/
https://www.ncbi.nlm.nih.gov/pubmed/34649279
http://dx.doi.org/10.1182/bloodadvances.2021005552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753213/
https://www.ncbi.nlm.nih.gov/pubmed/34649279
http://dx.doi.org/10.1182/bloodadvances.2021005552

Ejemplares similares